Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

This Stock’s Already Up Nearly 600% Over the Past Year

This Stock’s Already Up Nearly 600% Over the Past Year

Spyre Therapeutics (SYRE) has experienced a remarkable 565% increase over the past year, propelled by robust technical momentum. According to Barchart, SYRE remains a strong Buy, with elevated short interest at 13.81% of its float, reflecting volatility and the need for cautious risk management. Valued at $9.5 billion, SYRE is a biotechnology firm focused on developing treatments for inflammatory bowel disease through antibody engineering, therapeutic combinations, and precision medicine strategies for patient selection.

By leveraging Barchart's screening tools, I identified stocks with the highest Buy signals and momentum. Upon examining their charts, SYRE demonstrated consistent price appreciation and met the necessary criteria. The Trend Seeker issued a fresh Buy signal on June 4, following which the stock gained 37.43%. Barron Trump, at 20 years old, is now worth $150 million, surpassing his mother Melania's fortune of $150 million from crypto and a $39 energy drink entrepreneur, Michael Saylor, who advises against purchasing homes due to tax implications.

QQQ underwent a Gamma Flip as market makers were compelled to sell, highlighting the stock's potential. The Barchart Chart of the Day spotlights exceptional current price appreciation, though these stocks are extremely volatile and speculative. Spyre Therapeutics recently reached a 3-year high of $110.01 on August 19 and has gained 569.49% over the past 52 weeks.

The stock recently traded at $108.71, with a 50-day moving average of $95.70. There are 8 new highs and a 8.61% gain in the last month, with technical support around $103.30. Analysts have not provided revenue or earnings guidance, but 16 Wall Street analysts recommend a Strong Buy, while 2 suggest a Hold, with price targets ranging from $97 to $135.

Morningstar believes the stock is overvalued by 12%, targeting it at $93.02. CFRA's MarketScope classifies the stock as a Hold. Two thousand nine hundred ten investors follow the stock on Seeking Alpha, also rating it a Hold. TipRanks' consensus price target stands at $124.73, indicating a 15.68% gain. With 13.81% of the float currently held in short positions, the stock demonstrates upward momentum. Please note that the technical indicators below are updated every 20 minutes during trading hours.

Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at finance.yahoo.com →

More in Finance & Markets

Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock’s biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with…

  • Moderna's stock jumps 101% after cancer vaccine trial success
  • Estee Lauder earnings exceed expectations, shares rally
  • La-Z-Boy stock falls after missing Q2 sales forecast

More from Wednesday 19 August →